Selinexor
- Generic Name
- Selinexor
- Brand Names
- Xpovio 100 Mg Once Weekly Carton, Nexpovio
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11F6N7O
- CAS Number
- 1393477-72-9
- Unique Ingredient Identifier
- 31TZ62FO8F
- Background
Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with bortezomib and dexamethasone, is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells. This condition is typically treated with high dose bortezomib and dexamethasone chemothe...
- Indication
Selinexor is indicated in combination with bortezomib and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Selinexor is also indicated in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma in adult patients who have received at least four prior therapi...
- Associated Conditions
- Multiple Myeloma (MM), Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Relapsed Diffuse large B-cell lymphoma NOS
- Associated Therapies
- -
Twice-per-weekSelinexor, 2 Days Melphalan
- Conditions
- Interventions
- First Posted Date
- 2024-09-25
- Last Posted Date
- 2024-09-25
- Target Recruit Count
- 126
- Registration Number
- NCT06613035
- Locations
- 🇨🇳
Zhengzhou University First Affiliated Hospital, Zhengzhou, Henan, China
🇨🇳Hebei Medical University Second Hospital, Shijiazhuang, hebeisheng, China
🇨🇳The 960th Hospital of the Joint Service Support Force of the Chinese People's Liberation Army, Jinan, Shandong, China
A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-08-15
- Target Recruit Count
- 38
- Registration Number
- NCT06556199
- Locations
- 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hanzhou, Zhejiang, China
Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-08-14
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 37
- Registration Number
- NCT06552559
- Locations
- 🇰🇷
Samsung Cancer Research Institute, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
Telehealth-based Symptom Management for Veterans Treated With Selinexor
- Conditions
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Durham VA Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT06452446
Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2024-06-10
- Last Posted Date
- 2024-06-10
- Target Recruit Count
- 20
- Registration Number
- NCT06449482
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 139
- Registration Number
- NCT06239272
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
A Trial of Selinexor, Ruxolitinib and Methylprednisolone
- Conditions
- Interventions
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Oncotherapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT06225310
Selinexor, Cyclophosphamide and Prednisone in Myeloma
- Conditions
- Interventions
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- University of Leeds
- Target Recruit Count
- 66
- Registration Number
- NCT06212596
- Locations
- 🇬🇧
Guys and St Thomas NHS Foundation Trust, London, United Kingdom
🇬🇧Imperial College Healthcare NHS Trust, London, United Kingdom
🇬🇧Royal Bournemouth Hospital, Bournemouth, United Kingdom
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyDrug: BortezomibProcedure: Computed TomographyBiological: DaratumumabDrug: Daratumumab and Recombinant Human HyaluronidaseDrug: DexamethasoneDrug: LenalidomideProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyDrug: Selinexor
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT06169215
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States
🇺🇸UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 380
- Registration Number
- NCT06158841
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 260883, Hangzhou, Zhejiang, China
🇺🇸Alta Bates Summit Medical Center for Research /ID# 261438, Berkeley, California, United States
🇺🇸Providence - St. Jude Medical Center /ID# 262031, Fullerton, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.